Aura Biosciences (NASDAQ:AURA) Raised to Strong-Buy at Evercore ISI

Evercore ISI upgraded shares of Aura Biosciences (NASDAQ:AURA) to a strong-buy rating in a research report released on Monday morning, Zacks.com reports.

Several other equities research analysts also recently commented on AURA. Lifesci Capital upgraded shares of Aura Biosciences to a strong-buy rating in a research report on Monday, September 9th. HC Wainwright restated a buy rating and issued a $21.00 target price on shares of Aura Biosciences in a report on Friday, September 13th. Finally, JMP Securities raised their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a market outperform rating in a research report on Friday, September 13th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Buy and an average price target of $21.67.

Aura Biosciences Stock Down 0.2 %

Shares of Aura Biosciences stock opened at $9.55 on Monday. Aura Biosciences has a 12-month low of $5.99 and a 12-month high of $12.35. The firm has a market capitalization of $473.14 million, a PE ratio of -5.13 and a beta of 0.35. The stock’s fifty day moving average is $8.66 and its 200-day moving average is $7.89.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.04. Analysts expect that Aura Biosciences will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. purchased a new position in shares of Aura Biosciences during the 2nd quarter valued at $119,000. American International Group Inc. grew its stake in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new position in Aura Biosciences in the 1st quarter worth about $144,000. Trexquant Investment LP raised its stake in shares of Aura Biosciences by 64.5% during the 4th quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after purchasing an additional 6,809 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.